However, in Taiwan, oncologists who are involved in the treatment of breast cancer must prescribe in line with the requirements of the NHI and estrogen receptor positive breast cancer needs to be confirmed when claiming reimbursement from the NHI. This evidence concerns the gene ESR1 and breast cancer.